Evogene Historical Balance Sheet

EVGN Stock

USD 1.61 0.08 4.73%

Trend analysis of Evogene balance sheet accounts such as Other Current Liabilities of 2.8 M or Total Current Liabilities of 5.6 M provides information on Evogene's total assets, liabilities, and equity, which is the actual value of Evogene to its prevalent stockholders. By breaking down trends over time using Evogene balance sheet statements, investors will see what precisely the company owns and what it owes to creditors or other parties at the end of each accounting year.

Cash Flow Balance Sheet Income Statement

Yuan Drop

Covid

Financial Statement Analysis is much more than just reviewing and examining Evogene latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Evogene is a good buy for the upcoming year.

Evogene Inventory

79,800

Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Evogene. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price.

To learn how to invest in Evogene Stock, please use our How to Invest in Evogene guide.

About Evogene Balance Sheet Analysis

Balance Sheet is a snapshot of the financial position of Evogene at a specified time, usually calculated after every quarter, six months, or one year. Evogene Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of Evogene and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which Evogene currently owns. An asset can also be divided into two categories, current and non-current.

Evogene Balance Sheet Chart

At this time, Evogene's Non Currrent Assets Other are very stable compared to the past year. As of the 29th of November 2024, Cash And Short Term Investments is likely to grow to about 55.2 M, while Common Stock Shares Outstanding is likely to drop about 4.3 M.

Common Stock Shares Outstanding Other Current Liab Total Current Liabilities Other Liab Cash

Add Fundamental

Common Stock Shares Outstanding

The total number of shares of a company's common stock that are currently owned by all its shareholders.

Total Current Liabilities

Total Current Liabilities is an item on Evogene balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Evogene are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.

Cash

Cash refers to the most liquid asset of Evogene, which is listed under current asset account on Evogene balance sheet and usually includes currency, coins, checking accounts, and not deposited checks received from Evogene customers. The amounts must be unrestricted with restricted cash listed in a different Evogene account. The total amount of money in the form of currency that a company has in its possession. This includes all bills, coins, and funds in bank accounts.

Most accounts from Evogene's balance sheet are interrelated and interconnected. However, analyzing balance sheet accounts one by one will only give a small insight into Evogene current financial condition. On the other hand, looking into the entire matrix of balance sheet accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Evogene. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price.

To learn how to invest in Evogene Stock, please use our How to Invest in Evogene guide.At this time, Evogene's Non Currrent Assets Other are very stable compared to the past year. As of the 29th of November 2024, Cash And Short Term Investments is likely to grow to about 55.2 M, while Common Stock Shares Outstanding is likely to drop about 4.3 M.

	2021	2022	2023	2024 (projected)
Total Current Liabilities	6.9M	5.6M	6.9M	5.6M
Other Current Liabilities	4.3M	3.6M	3.9M	2.8M

Total Current Liabilities Other Current Liab

Evogene balance sheet Correlations

	Total Assets	Common Stock Shares Outstanding	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Other Liab	Accounts Payable	Cash	Other Assets	Short Term Investments	Other Current Assets	Total Liab	Intangible Assets	Common Stock	Property Plant Equipment	Property Plant And Equipment Net	Current Deferred Revenue	Net Debt	Retained Earnings	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments	Net Receivables	Common Stock Total Equity	Non Current Liabilities Total	Other Stockholder Equity
Total Assets		0.35	-0.49	0.09	0.95	-0.54	0.47	0.33	-0.2	0.6	0.64	-0.51	0.0	-0.33	0.69	0.67	0.02	-0.39	0.53	-0.3	-0.31	0.97	0.7	-0.26	-0.57	-0.15
Common Stock Shares Outstanding	0.35		-0.31	-0.04	0.52	-0.48	0.34	-0.36	-0.15	0.69	0.3	-0.42	-0.15	-0.8	0.57	0.59	0.5	0.11	0.77	-0.65	-0.19	0.44	0.36	-0.78	-0.65	-0.63
Other Current Liab	-0.49	-0.31		0.53	-0.53	0.36	0.04	0.06	0.13	-0.51	-0.49	0.65	-0.27	0.19	-0.26	-0.23	0.17	-0.18	-0.2	0.49	0.2	-0.58	-0.15	0.19	0.31	-0.09
Total Current Liabilities	0.09	-0.04	0.53		0.06	0.02	0.46	0.32	0.0	-0.15	-0.21	0.49	-0.69	-0.25	0.37	0.39	0.66	-0.52	0.45	0.02	0.17	0.03	0.24	-0.24	-0.08	-0.59
Total Stockholder Equity	0.95	0.52	-0.53	0.06		-0.72	0.42	0.19	-0.15	0.71	0.61	-0.61	0.03	-0.46	0.69	0.68	0.11	-0.32	0.66	-0.44	-0.32	0.95	0.71	-0.37	-0.76	-0.25
Other Liab	-0.54	-0.48	0.36	0.02	-0.72		0.11	-0.06	0.31	-0.47	-0.31	0.8	-0.31	0.42	-0.26	-0.27	0.04	0.19	-0.49	0.23	0.61	-0.53	-0.58	0.28	0.95	0.13
Accounts Payable	0.47	0.34	0.04	0.46	0.42	0.11		0.0	-0.05	0.44	0.29	0.28	-0.57	-0.28	0.7	0.7	0.6	-0.22	0.57	-0.37	0.21	0.47	0.32	-0.36	-0.11	-0.52
Cash	0.33	-0.36	0.06	0.32	0.19	-0.06	0.0		0.02	-0.54	-0.39	0.08	-0.3	0.19	-0.08	-0.09	-0.16	-0.92	-0.09	0.35	-0.01	0.23	0.28	0.23	0.06	0.16
Other Assets	-0.2	-0.15	0.13	0.0	-0.15	0.31	-0.05	0.02		-0.17	-0.2	0.46	-0.18	0.1	-0.03	-0.01	0.11	-0.02	-0.05	0.11	0.88	-0.23	-0.17	0.06	0.35	-0.01
Short Term Investments	0.6	0.69	-0.51	-0.15	0.71	-0.47	0.44	-0.54	-0.17		0.81	-0.52	0.16	-0.54	0.68	0.68	0.26	0.38	0.64	-0.69	-0.23	0.69	0.38	-0.51	-0.62	-0.36
Other Current Assets	0.64	0.3	-0.49	-0.21	0.61	-0.31	0.29	-0.39	-0.2	0.81		-0.44	0.43	-0.15	0.57	0.55	-0.12	0.41	0.26	-0.27	-0.29	0.64	0.37	-0.11	-0.33	0.02
Total Liab	-0.51	-0.42	0.65	0.49	-0.61	0.8	0.28	0.08	0.46	-0.52	-0.44		-0.52	0.34	-0.12	-0.11	0.31	-0.1	-0.23	0.34	0.7	-0.56	-0.37	0.23	0.75	-0.11
Intangible Assets	0.0	-0.15	-0.27	-0.69	0.03	-0.31	-0.57	-0.3	-0.18	0.16	0.43	-0.52		0.44	-0.41	-0.42	-0.83	0.5	-0.52	0.3	-0.49	-0.04	-0.03	0.54	-0.13	0.75
Common Stock	-0.33	-0.8	0.19	-0.25	-0.46	0.42	-0.28	0.19	0.1	-0.54	-0.15	0.34	0.44		-0.68	-0.7	-0.72	0.08	-0.89	0.67	0.08	-0.44	-0.4	0.98	0.6	0.87
Property Plant Equipment	0.69	0.57	-0.26	0.37	0.69	-0.26	0.7	-0.08	-0.03	0.68	0.57	-0.12	-0.41	-0.68		1.0	0.6	-0.12	0.82	-0.45	0.05	0.7	0.63	-0.69	-0.41	-0.7
Property Plant And Equipment Net	0.67	0.59	-0.23	0.39	0.68	-0.27	0.7	-0.09	-0.01	0.68	0.55	-0.11	-0.42	-0.7	1.0		0.63	-0.13	0.85	-0.46	0.07	0.69	0.63	-0.71	-0.43	-0.73
Current Deferred Revenue	0.02	0.5	0.17	0.66	0.11	0.04	0.6	-0.16	0.11	0.26	-0.12	0.31	-0.83	-0.72	0.6	0.63		-0.14	0.78	-0.53	0.36	0.11	0.1	-0.79	-0.19	-0.95
Net Debt	-0.39	0.11	-0.18	-0.52	-0.32	0.19	-0.22	-0.92	-0.02	0.38	0.41	-0.1	0.5	0.08	-0.12	-0.13	-0.14		-0.22	-0.18	0.0	-0.31	-0.41	0.04	0.16	0.15
Retained Earnings	0.53	0.77	-0.2	0.45	0.66	-0.49	0.57	-0.09	-0.05	0.64	0.26	-0.23	-0.52	-0.89	0.82	0.85	0.78	-0.22		-0.68	-0.02	0.6	0.54	-0.87	-0.68	-0.88
Non Current Assets Total	-0.3	-0.65	0.49	0.02	-0.44	0.23	-0.37	0.35	0.11	-0.69	-0.27	0.34	0.3	0.67	-0.45	-0.46	-0.53	-0.18	-0.68		-0.01	-0.5	-0.07	0.69	0.44	0.58
Non Currrent Assets Other	-0.31	-0.19	0.2	0.17	-0.32	0.61	0.21	-0.01	0.88	-0.23	-0.29	0.7	-0.49	0.08	0.05	0.07	0.36	0.0	-0.02	-0.01		-0.3	-0.31	-0.04	0.57	-0.19
Cash And Short Term Investments	0.97	0.44	-0.58	0.03	0.95	-0.53	0.47	0.23	-0.23	0.69	0.64	-0.56	-0.04	-0.44	0.7	0.69	0.11	-0.31	0.6	-0.5	-0.3		0.63	-0.38	-0.59	-0.24
Net Receivables	0.7	0.36	-0.15	0.24	0.71	-0.58	0.32	0.28	-0.17	0.38	0.37	-0.37	-0.03	-0.4	0.63	0.63	0.1	-0.41	0.54	-0.07	-0.31	0.63		-0.3	-0.59	-0.27
Common Stock Total Equity	-0.26	-0.78	0.19	-0.24	-0.37	0.28	-0.36	0.23	0.06	-0.51	-0.11	0.23	0.54	0.98	-0.69	-0.71	-0.79	0.04	-0.87	0.69	-0.04	-0.38	-0.3		0.48	0.91
Non Current Liabilities Total	-0.57	-0.65	0.31	-0.08	-0.76	0.95	-0.11	0.06	0.35	-0.62	-0.33	0.75	-0.13	0.6	-0.41	-0.43	-0.19	0.16	-0.68	0.44	0.57	-0.59	-0.59	0.48		0.35
Other Stockholder Equity	-0.15	-0.63	-0.09	-0.59	-0.25	0.13	-0.52	0.16	-0.01	-0.36	0.02	-0.11	0.75	0.87	-0.7	-0.73	-0.95	0.15	-0.88	0.58	-0.19	-0.24	-0.27	0.91	0.35

Click cells to compare fundamentals

Evogene Account Relationship Matchups

Evogene balance sheet Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	71.4M	71.9M	76.3M	56.1M	51.1M	65.0M
Common Stock Shares Outstanding	25.8M	2.8M	4.0M	4.1M	4.6M	4.3M
Other Current Liab	3.4M	8.0M	4.3M	3.6M	3.9M	2.8M
Total Current Liabilities	5.7M	9.7M	6.9M	5.6M	6.9M	5.6M
Total Stockholder Equity	50.1M	46.0M	54.0M	27.9M	12.1M	11.5M
Other Liab	3.3M	3.7M	4.3M	14.8M	17.0M	17.8M
Accounts Payable	1.0M	863K	1.5M	1.0M	1.8M	1.2M
Cash	34.7M	46.2M	32.3M	29.0M	20.8M	26.8M
Short Term Investments	12.1M	2M	21.5M	6.4M	10.3M	9.8M
Other Current Assets	894K	1.4M	1.7M	1.0M	2.7M	5.0M
Total Liab	11.1M	15.0M	12.9M	21.3M	22.4M	15.0M
Property Plant Equipment	5.3M	3.9M	4.2M	4.1M	3.7M	4.7M
Property Plant And Equipment Net	5.3M	3.9M	4.2M	4.1M	3.4M	4.5M
Current Deferred Revenue	423K	119K	264K	101K	362K	343.9K
Net Debt	(31.8M)	(43.8M)	(29.7M)	(17.1M)	(9.3M)	(9.7M)
Retained Earnings	(155.9M)	(179.3M)	(207.1M)	(233.7M)	(257.6M)	(244.7M)
Non Current Assets Total	22.3M	20.1M	19.4M	18.4M	16.6M	13.2M
Cash And Short Term Investments	46.9M	48.2M	53.9M	35.4M	31.1M	55.2M
Net Receivables	2.2M	2.2M	1.2M	803K	671K	637.5K
Liabilities And Stockholders Equity	71.4M	71.9M	76.3M	56.1M	51.1M	66.8M
Non Current Liabilities Total	5.4M	5.4M	6.0M	15.7M	15.5M	16.2M
Other Stockholder Equity	205.9M	225.1M	260.5M	261.4M	269.4M	225.1M
Property Plant And Equipment Gross	5.3M	3.9M	4.2M	4.1M	26.0M	27.3M
Total Current Assets	49.0M	51.8M	56.9M	37.8M	34.5M	57.2M
Accumulated Other Comprehensive Income	205.9M	225.1M	260.5M	261.4M	269.4M	282.8M
Short Term Debt	895K	777K	974K	1.8M	853K	1.7M
Net Tangible Assets	33.1M	29.9M	38.8M	13.8M	12.4M	11.8M
Inventory	(894K)	(1.4M)	92K	566K	76K	79.8K
Non Current Liabilities Other	3.4M	2.9M	3.3M	3.7M	4.2M	3.7M
Net Invested Capital	50.1M	46.0M	54.0M	38.0M	22.4M	37.7M
Net Working Capital	43.3M	42.1M	50.0M	32.1M	27.5M	35.8M

Pair Trading with Evogene

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Evogene position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Evogene will appreciate offsetting losses from the drop in the long position's value.

Moving against Evogene Stock

0.86	GILD	Gilead Sciences	Pair Corr
0.85	BMY	Bristol Myers Squibb Sell-off Trend	Pair Corr
0.8	ESPR	Esperion Therapeutics Buyout Trend	Pair Corr
0.73	EWTX	Edgewise Therapeutics	Pair Corr
0.71	VTRS	Viatris	Pair Corr

The ability to find closely correlated positions to Evogene could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Evogene when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Evogene - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Evogene to buy it.

The correlation of Evogene is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Evogene moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Evogene moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.

Correlation analysis and pair trading evaluation for Evogene can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.

Pair Correlation Correlation Matching

When determining whether Evogene offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Evogene's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Evogene Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Evogene Stock:

How To Invest In Evogene

Details

Is Evogene Stock a good investment?

Details

What is Evogene's Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

To learn how to invest in Evogene Stock, please use our How to Invest in Evogene guide.

You can also try the USA ETFs module to find actively traded Exchange Traded Funds (ETF) in USA.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Evogene. If investors know Evogene will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Evogene listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(4.46)

Revenue Per Share

1.881

Quarterly Revenue Growth

0.398

Return On Assets

(0.28)

Return On Equity

(0.82)

The market value of Evogene is measured differently than its book value, which is the value of Evogene that is recorded on the company's balance sheet. Investors also form their own opinion of Evogene's value that differs from its market value or its book value, called intrinsic value, which is Evogene's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Evogene's market value can be influenced by many factors that don't directly affect Evogene's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Evogene's value and its price as these two are different measures arrived at by different means. Investors typically determine if Evogene is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Evogene's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Evogene Historical Balance Sheet

Evogene Inventory

79,800

About Evogene Balance Sheet Analysis

Evogene Balance Sheet Chart

Common Stock Shares Outstanding

Total Current Liabilities

Cash

Evogene balance sheet Correlations

Evogene Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Evogene balance sheet Accounts

Pair Trading with Evogene

Moving against Evogene Stock

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Property Plant And Equipment Net	+ 1.0	Property Plant Equipment
Common Stock Total Equity	+ 0.98	Common Stock
Cash And Short Term Investments	+ 0.97	Total Assets
Total Stockholder Equity	+ 0.95	Total Assets
Cash And Short Term Investments	+ 0.95	Total Stockholder Equity
Non Current Liabilities Total	+ 0.95	Other Liab

Other Stockholder Equity	- 0.95	Current Deferred Revenue
Net Debt	- 0.92	Cash
Retained Earnings	- 0.89	Common Stock
Other Stockholder Equity	- 0.88	Retained Earnings
Common Stock Total Equity	- 0.87	Retained Earnings
Current Deferred Revenue	- 0.83	Intangible Assets